UBS ASSET MANAGEMENT AMERICAS LLC - ALLOGENE THERAPEUTICS INC ownership

ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 179 filers reported holding ALLOGENE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.67 and the average weighting 0.1%.

Quarter-by-quarter ownership
UBS ASSET MANAGEMENT AMERICAS LLC ownership history of ALLOGENE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$496,768
-81.1%
156,709
-70.6%
0.00%
-100.0%
Q2 2023$2,634,1850.0%533,2360.0%0.00%0.0%
Q1 2023$2,634,185
-100.0%
533,236
+5.4%
0.00%
-66.7%
Q3 2022$5,466,281,000
+12.5%
506,137
+18.7%
0.00%0.0%
Q2 2022$4,859,615,000
+32.4%
426,282
+5.8%
0.00%
+50.0%
Q1 2022$3,670,028,000
-36.9%
402,857
+3.3%
0.00%0.0%
Q4 2021$5,818,233,000
-41.6%
389,962
+0.5%
0.00%
-50.0%
Q3 2021$9,970,083,000
-4.0%
387,941
-2.6%
0.00%0.0%
Q2 2021$10,384,535,000
+31.3%
398,180
+76.6%
0.00%
+33.3%
Q1 2021$7,908,084,000
+18.5%
225,491
-14.7%
0.00%0.0%
Q4 2020$6,671,060,000
-32.0%
264,305
+1.5%
0.00%
-40.0%
Q3 2020$9,817,572,000
-7.0%
260,344
+5.7%
0.01%
-16.7%
Q2 2020$10,551,320,000
+197.1%
246,411
+34.9%
0.01%
+100.0%
Q1 2020$3,551,377,000
-33.1%
182,684
-10.6%
0.00%0.0%
Q4 2019$5,308,026,000
-0.2%
204,312
+4.7%
0.00%
-25.0%
Q3 2019$5,317,071,000
-1.1%
195,086
-2.6%
0.00%0.0%
Q2 2019$5,377,169,000
-6.1%
200,267
+1.1%
0.00%0.0%
Q1 2019$5,727,794,000
+122.0%
198,125
+106.8%
0.00%
+100.0%
Q4 2018$2,580,486,00095,8220.00%
Other shareholders
ALLOGENE THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
VV Manager LLC 1,798,163$76,997,00067.53%
Wildcat Capital Management, LLC 1,515,524$64,895,00022.42%
TPG Group Holdings (SBS) Advisors, Inc. 19,716,306$844,252,00014.91%
REGENTS OF THE UNIVERSITY OF CALIFORNIA 1,279,281$54,779,0007.69%
Coastal Bridge Advisors, LLC 463,117$19,831,0006.33%
DSAM Partners (London) Ltd 235,098$10,067,0002.63%
Casdin Capital, LLC 625,000$26,763,0001.58%
Alpine Global Management, LLC 150,000$6,423,0001.13%
Perceptive Advisors 1,543,790$66,105,0001.07%
Avoro Capital Advisors LLC 1,128,594$48,326,0000.96%
View complete list of ALLOGENE THERAPEUTICS INC shareholders